112257-20-2 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
3-AMINOMETHYL-AZETIDINE-1-CARBOXYLIC ACID BENZYL ESTER is utilized as a key intermediate in the synthesis of potential therapeutic agents, contributing to the advancement of new drugs for the treatment of various medical conditions. Its unique structure and reactivity make it a valuable component in the development of pharmaceuticals with novel mechanisms of action.
Used as a Building Block in Organic Synthesis:
In addition to its pharmaceutical applications, 3-AMINOMETHYL-AZETIDINE-1-CARBOXYLIC ACID BENZYL ESTER may also serve as a building block in the synthesis of other organic compounds for various industrial purposes. Its versatility in chemical reactions allows it to be incorporated into a wide range of organic molecules, expanding its utility beyond the pharmaceutical sector.
Check Digit Verification of cas no
The CAS Registry Mumber 112257-20-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,2,2,5 and 7 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 112257-20:
(8*1)+(7*1)+(6*2)+(5*2)+(4*5)+(3*7)+(2*2)+(1*0)=82
82 % 10 = 2
So 112257-20-2 is a valid CAS Registry Number.
InChI:InChI=1/C11H14N2O2/c12-10-6-13(7-10)11(14)15-8-9-4-2-1-3-5-9/h1-5,10H,6-8,12H2
112257-20-2Relevant academic research and scientific papers
Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides
Tarr, James C.,Wood, Michael R.,Noetzel, Meredith J.,Bertron, Jeanette L.,Weiner, Rebecca L.,Rodriguez, Alice L.,Lamsal, Atin,Byers, Frank W.,Chang, Sichen,Cho, Hyekyung P.,Jones, Carrie K.,Niswender, Colleen M.,Wood, Michael W.,Brandon, Nicholas J.,Duggan, Mark E.,Conn, P. Jeffrey,Bridges, Thomas M.,Lindsley, Craig W.
, p. 2990 - 2995 (2017/05/31)
This letter details the continued chemical optimization of a novel series of M4 positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c]pyridazine core by incorporating a 3-amino azetidine amide moiety. The analogs described within this work represent the most potent M4 PAMs reported for this series to date. The SAR to address potency, clearance, subtype selectivity, CNS exposure, and P-gp efflux are described. This work culminated in the discovery of VU6000918, which demonstrated robust efficacy in a rat amphetamine-induced hyperlocomotion reversal model at a minimum efficacious dose of 0.3?mg/kg.
